Pharmacy

As the opioid epidemic rages, up-and-coming physicians are seen as part of the solution. Here’s how medical schools are changing their training programs.

New medicine for Duchenne muscular dystrophy raises questions. Here’s whose covering it and why.

The next few years will see the healthcare industry bracing itself for new biosimilar products for a range of illnesses from oncology to rheumatoid arthritis.

An eye-opening study by Precision for Value assesses cancer value frameworks.

Here are three ways HealthPartners’ health plan and care delivery system work together to save customers time and money and improve their experience.

By using a patient-centered, physician-led model of care, Blue Cross Blue Shield (BCBS) of Michigan lowers recidivism and healthcare costs.

An Avalere study has interesting findings about payer acceptance of biosimilars.

Uncover the root causes of why patients become nonadherent and be better positioned to improve the lives of patients and reduce costs through improved health outcomes.

Analysts discuss how pharmacoeconomics will make a difference in treatment decisions.

Payers realize value in partnering with pharmacists to manage medication-related complications

Cost burden prompts payers to consider appropriate utilization

A National Lipid Association survey has interesting findings on the prescription approval process for PCSK9 inhibitors.

To identify the top managed care pharmacy challenges and what your peers are doing about them, Managed Healthcare Executive conducted its annual pharmacy survey during the first quarter of 2017.

One expert believes managed care executives are key to a necessary paradigm shift in pediatric polypharmacy.

The conference raised important points about unregulated growth opportunities and new pharmacy arena players.

WalletHub released a study comparing 50 states and the District in terms of 15 key metrics, ranging from arrest and overdose rates to opioid prescriptions and meth-lab incidents per capita.

HealthPartners aims to improve price information for consumers. Here’s how.

Although drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.

MCOs are fighting back against rising pharmaceutical costs. Here are the top strategies they are embracing.

Alternatives to opioids programs emerge as viable tools to mitigate the crisis.

The days of the traditional, channel-focused and largely enshrouded PBM business model have come and gone. Here’s what’s next.

Technology advances in pharmacy include innovations that improve medication safety, efficiency, and patient compliance.

Value-based drug contracting between manufacturers and payers is picking up steam-appropriate timing as the healthcare industry moves toward value-based payment and purchasing and away from fee-for-service.

Operational issues aside, outcomes-based contracts can offer a two-fold benefit for managed care executives.

Here are the top three reasons for medication adherence failure and how to overcome them.